ReviewFrontiers in immunology2025
Regulatory effects of traditional Chinese medicine on the breast-cancer immune microenvironment.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common malignant tumor in women, driven by various factors. Its incidence has been rising annually and has become an urgent global public health challenge. An increasing body of evidence suggests that the immune microenvironment (IME) of breast cancer plays a crucial role in tumor initiation, progression, and metastasis. Through multi-target and multi-pathway regulatory effects, Traditional Chinese Medicine (TCM) demonstrates unique potential in reshaping the tumor immune microenvironment (TIME). This narrative review aims to systematically organize and summarize recent mechanistic advancements, elucidating how Traditional Chinese Medicine (primarily based on Chinese herbal medicine) regulates the function and polarization of key immune cells, controls immune checkpoints and cytokine networks, thereby inhibiting tumor immune escape, enhancing anti-tumor immunity, and exerting anti-BC effects. Despite the promising prospects, the application of TCM in BC immunotherapy still faces numerous challenges, including tumor heterogeneity, dosage complexity, and safety issues. Future research should focus on large-scale, multi-center clinical trials combining contemporary immunotherapy strategies, aiming to achieve better clinical outcomes in BC treatment and provide insights for immunotherapy of other cancer types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.